secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K/A
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001104659-25-047844
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tvardi Q1 2025 net loss $9.6M, cash burn $7.7M; going concern doubt persists
----------------------------------------------------------------------------

- Net loss $9.6M ($0.50 dil EPS) vs $4.2M loss in Q1 2024; accumulated deficit $101.8M.
- Revenue nil; operating expenses $4.35M (R&D $3.1M, G&A $1.2M).
- Cash & equivalents $11.4M, short-term investments $10.9M at March 31; cash used in ops $7.7M.
- Convertible notes $35.8M; other expense $5.5M from fair value change on notes.
- Merger closed April 15, 2025 provided $23.8M cash; substantial doubt about going concern pre-merger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465925047844/0001104659-25-047844-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465925047844/tm2514727d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-047844

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer